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Abstract
Background: Carbapenem-nonsusceptible A. baumannii-calcoaceticus complex have emerged worldwide, but the
epidemiology in Indonesian hospitals has not been studied.
Methods: A prospective observational study was performed on the intensive care units (ICUs) of the national referral
hospital in Jakarta-Indonesia, in 2013 and 2014. All consecutive adult patients admitted and hospitalized for >48 h in
ICUs were included. Basic and clinical data at admission were recorded. Carbapenem-nonsusceptible A. baumannii-
calcoaceticus complex from clinical cultures and standardized screening were included. Environmental niches and
healthcare workers (HCWs) were also screened. PCR was used to detect carbapenemase genes, and Raman
spectroscopy as well as multilocus sequence typing (MLST) for typing.
Results: Of 412 included patients, 69 (16.7%) carried carbapenem-nonsusceptible A. baumannii-calcoaceticus complex
on admission, and 89 (25.9%) became positive during ICU stay. The acquisition rate was 43 per 1000 patient-days at
risk. Six isolates were cultured from environment and one from a HCW. Acquisition of carbapenem-nonsusceptible A.
baumannii-calcoaceticus complex was associated with longer ICU stay (median interquartile range [IQR]: 11 days [5–18],
adjusted hazard ratio [aHR]: 2.56 [99% confidence interval (CI):1.76–3.70]), but not with mortality (adjusted odds ratio: 1.
59 [99%CI: 0.74–3.40] at the chosen level of significance). The blaOXA-23-like gene was detected in 292/318
(91.8%) isolates, including isolates from the environment and HCW. Typing revealed five major clusters. Sequence types
(ST)195, ST208, ST218, ST642 as well as new STs were found. The dominant clone consisted of isolates from patients
and environment throughout the study period.
Conclusions: Carbapenem-nonsusceptible A. baumannii-calcoaceticus complex are endemic in this setting. Prevention
requires source control and limiting transmission of strains.
Trial registration: The study was retrospectively registered at www.trialregister.nl (No:5541). Candidate number: 23,527,
NTR number: NTR5541, Date registered NTR: 22nd December 2015.
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Background
Multidrug-resistant Acinetobacter baumannii-calcoaceticus
complex has emerged as one of the most problematic
pathogens in hospitals. Their natural habitat is in the
environment, including niches in the hospital from
which they can spread to patients [1]. Risk factors for
colonization and infection with multidrug-resistant A.
baumannii-calcoaceticus complex include length of
hospital stay, admission to an intensive care unit
(ICU), mechanical ventilation, antimicrobial exposure,
and several other factors [2]. Carbapenem-nonsusceptible
A. baumannii-calcoaceticus complex is considered a sig-
nificant health problem because of the limited options
remaining for antibiotic treatment [3].
In 2013, the Centers for Disease Control and Preven-
tion of the United States reported an estimated 12,000
healthcare-associated Acinetobacter infections. Nearly
7000 of these were caused by multidrug-resistant isolates
[4]. In 2008, Lagamayo et al. reported that between 2 and
77% of all clinical isolates of Acinetobacter spp. in Asian
countries were resistant to imipenem, and that multidrug-
resistant Acinetobacter spp. were highly prevalent, particu-
larly in Thailand and India, but not in the Philippines [5].
To date, there have been no data on the epidemiology of
carbapenem-resistant or -nonsusceptible A. baumannii-
calcoaceticus complex from Indonesia, the fourth most
populous country in the world. This study was designed
to delineate the clinical and molecular epidemiology of
carbapenem-nonsusceptible A. baumannii-calcoaceticus
complex in two ICUs of the national referral hospital in
Jakarta, Indonesia.
Methods
Study design
A prospective observational study was performed at the Dr.
Cipto Mangunkusumo General Hospital, a 1000-bed teach-
ing hospital in Jakarta, Indonesia, from April–October 2013
and from April–August 2014. We conducted this study in
two ICUs: the 12-bedded adult ICU and the 8-bedded
Emergency Room (ER)-ICU with an average of 1010 and
415 admissions per year, respectively. The adult ICU is an
open ward with mechanical ventilation facilities, admitting
patients with mixed medical and surgical indications, and
one designated nurse per patient during first shifts (7 am-
3 pm) and a 1:1.5 nurse/patient ratio during other shifts.
The ER-ICU has the same design, and the nurse-to-patient
ratio in the first shifts is 1:1 and during the other
shifts 1:2. The populations served by these two ICUs
were identical, and there was also no difference in
the service provided.
The study was performed in the framework of a lar-
ger study that focused on carbapenem-nonsusceptible
Klebsiella pneumoniae, Pseudomonas aeruginosa, and
A. baumannii-calcoaceticus complex.
All adult patients (≥18 years old) admitted to one of
the two ICUs and hospitalized for more than 48 h were
eligible for enrollment in this study. The first screening
cultures were taken on the day of admission, and if a pa-
tient was discharged before 48 h, he or she was excluded.
Informed consent was obtained from the patient or their
relatives as applicable. Demographic and clinical charac-
teristics such as age, gender, medical or surgical indication,
underlying diseases, hospitalization history, and previous
use of antibiotics were recorded on admission.
Systemic inflammatory response syndrome (SIRS) cri-
teria on admission were used as a screening tool to as-
sess (severity of ) septic illness. The SIRS criteria were
calculated and included in the study, as this was practice
at the time of the study [6].
The quick Sequential Organ Failure Assessment
(qSOFA) score is a new bedside prompt that may iden-
tify patients with suspected infection and helps to deter-
mine sepsis in all healthcare environments. The qSOFA
score assigns one point for each of the following condi-
tions: systolic blood pressure ≤ 100 mmHg, respiratory
rate ≥ 22 breaths per minute, and altered mentation
(Glasgow coma scale <15). A qSOFA score ≥ 2 at the on-
set of infection is associated with a greater risk of death
and prolonged ICU stay [6].
The primary outcome measure was acquisition of a
carbapenem-nonsusceptible A. baumannii-calcoaceticus
complex. Acquisition is defined as a screening culture or
clinical culture with first detection of A. baumannii-
calcoaceticus complex, with reduced susceptibility to a
carbapenem, that was not present within the first 48 h
of admission. Secondary outcome measures were length
of stay in the ICU, and mortality during ICU stay.
Environmental samples (Additional file 1: Table S1),
were taken twice (in October 2013 and December 2014),
simultaneously in both ICUs. Screening of healthcare
workers (HCWs) was performed once. HCWs were de-
fined as all personnel including doctors, nurses and
other people (cleaning staff, administration staff, porters,
nutritionist) working in one of the two ICUs during the
study period.
Screening method
From patients enrolled, screening cultures were obtained
from throat and rectum or stools by experienced ICU
nurses who had been trained for the task of taking the sam-
ples, on the day of admission, at the time of discharge from
the ICU, and weekly if the patient was admitted for seven
days or more. Sampling was performed using sterile cotton-
tipped swabs, and swabs were transported to the laboratory
in Amies transport medium (Oxoid, Basingstoke, UK). The
swabs in medium were transported in clean, closed boxes
at ambient temperature to the laboratory on the same day.
All swabs were processed in the laboratory within 24 h.
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Clinical samples were collected on indication from pa-
tients under aseptic precautions from the lower respira-
tory tract, blood, urine, tissue, or wound.
Environmental samples were taken from various sites, in-
cluding washbasins, bed rails, bedside cabinet tables, venti-
lators, and monitor screens (Additional file 1: Table S1),
with sterile cotton-tipped swabs and placed in Amies
transport medium.
All HCWs working in one of the ICUs were sampled
once over the course of one month (September 2013)
with sterile cotton-tipped swabs, which were transported
to the laboratory in Amies transport medium.
Microbiological methods
Isolation and identification
In the Clinical Microbiology Laboratory of Faculty of
Medicine, Universitas Indonesia, Jakarta, each swab was
placed in 5 ml trypticase soy broth (TSB) supplemented
with cefotaxime 2 mg/L plus vancomycin 50 mg/L and
incubated overnight. The next day, a loop of broth (10
μl) was subsequently subcultured onto MacConkey agar
(Oxoid) and incubated aerobically at 37 °C for 16–24 h,
following which identification using the VITEK2® system
(bioMérieux, Lyon, France) and susceptibility testing of
colonies suggestive of A. baumannii-calcoaceticus com-
plex was performed. All swabs, i.e. from patients, health-
care workers (HCWs), and environmental screening
were processed in the same way.
Blood cultures were collected in BACTEC® (BD,
Franklin Lakes, NJ, USA) bottles as per manufacturer’s
instructions at the discretion of attending clinicians with
a minimum of 10 ml of blood collected from at least
two puncture sites. Other clinical specimens were inocu-
lated onto blood and MacConkey agar plates and incu-
bated for 24 h at 37 °C. Subsequently, all colonies that
had been cultured were examined for morphology by
Gram stain and identified using the VITEK2® system.
Strains were stored in duplicate in −80 °C in TSB with
glycerol 10%. One tube of each strain was sent to the De-
partment of Medical Microbiology and Infectious Diseases,
Erasmus MC, Rotterdam, the Netherlands, which labora-
tory holds an ISO 15189 accreditation, for further analysis.
The other tube of each strain remained in the Indonesian
laboratory. In the Netherlands, the identity of strains was
confirmed using matrix-assisted laser desorption/ionisation
(Maldi Biotyper, Bruker Microflex LT, London, UK).
The quality control strains used for this part of the study
in Indonesia were Escherichia coli ATCC 25922 and
Pseudomonas aeruginosa ATCC 27853, in the laboratory
in Erasmus MC multiple quality control strains were used.
Antimicrobial susceptibility testing
The susceptibility of the screening isolates to imipenem
and meropenem was investigated by standard Kirby-Bauer
disc diffusion technique using Mueller-Hinton agar plates
(BD). For the isolates from clinical cultures, approxima-
tion of the minimum inhibitory concentrations (MICs)
of antibiotics was determined by the VITEK2® system.
Carbapenem zone sizes and MICs were interpreted ac-
cording to EUCAST (2013) using the following break-
points: meropenem zone size <21 mm and MIC >2 mg/L,
imipenem zone size <23 mm and MIC >2 mg/L. [7] For
this part of the study, quality control strains as described
above were used.
DNA extraction and carbapenemase gene detection
DNA from the isolates was extracted by a cell lysis
step and boiling using the InstaGene Matrix (Bio-Rad
Laboratories, USA) according to the manufacturer’s in-
structions. PCR-based detection of Ambler class B
metallo-beta-lactamases (blaNDM), class D beta-lactamases
(blaOXA-23-like, blaOXA-24-like, blaOXA-51-like and blaOXA-58-
like) and ISAba1 were carried out using a T3000 Thermo-
cycler (Biometra-Whatman, Goettingen). The upstream
location of the ISAba1 insertion element of the blaOXA-23-
like gene was demonstrated by using the ISAba1 forward
primer and the blaOXA-23-like reverse primer. PCR primers
and reaction conditions for PCR were as described previ-
ously [8–11]. Amplified PCR products were resolved by
electrophoresis at 250 V for 30 min on 1.5% agarose gels
with 0.5 x Tris (89 mM)-boric acid (89 mM)-EDTA(2 mM)
buffer containing SyBr® Safe DNA Gel Stain and visualized
under UV light and photographed. In each run, a positive
and negative control was included.
Clonal relatedness
Raman spectroscopy (SpectraCell RA® Bacterial Strain
Analyzer, RiverD International BV, Rotterdam, The
Netherlands) was applied as a first typing method [12, 13].
All isolates were grown overnight on trypticase soy agar
(TSA; BD). Samples were prepared and submitted to spec-
trometry as described previously [13]. Raman light scatter-
ings were analyzed by SpectraCellRA software version
1.9.0.13444:24. The similarity between pairs of spectra was
calculated using the squared Pearson correlation coeffi-
cient (R2-values), multiplied by 100 and expressed as a
percentage. The similarity threshold for this study was set
at 91% so that two isolates with an R2 below this threshold
were considered to be different and were designated dif-
ferent Raman types. Two isolates with an R2-value be-
tween 91% and 100% were considered indistinguishable
and were considered to have the same Raman type. Cor-
relation matrices displayed as 2D plots diagram were cre-
ated using MATLAB version 7.1 (The MathWorks,
Natick, MA, USA).
Multilocus sequence typing (MLST) was used as a sec-
ond typing method for a subset of isolates, including iso-
lates from the largest clones of Raman spectroscopy, and
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all isolates from blood cultures (one per patient). These
isolates were subjected to whole genome sequencing
(WGS) using Illumina chemistry. MLST typing results
were deduced from the WGS data and assigned based on
the Oxford database (pubmlst.org/abaumannii).
Statistical analysis
Statistical analyses were done using SPSS Version 24.0
(SPSS, Chicago, IL, USA). Patients admitted to adult
ICU were compared to ER-ICU using Chi square or
Fisher’s Exact and Mann-Whitney as appropriate. One-
way ANOVA was used to compare patient characteris-
tics according to their A. baumannii-calcoaceticus com-
plex status. Univariate and multivariate analyses were
performed to establish risk factors associated with mor-
tality using a multivariate logistic regression model with
backward selection and inclusion of variables with a p-
value <0.1 in the univariate analysis. Cox proportional
regression was used to analyse risk factors for length of
stay. Kaplan-Meier method was performed to construct
survival curves. P-values of less than 0.01 were consid-
ered significant [14].
Results
Patient characteristics
During the 11-month study period, 1211 patients were
hospitalized in the ICUs (Adult ICU: 863, ER-ICU: 348).
Additional file 1: Table S2 shows baseline characteristics
of patients in each ICU. Of the 412 included patients,
188 were admitted to the adult ICU and 224 to the ER-
ICU. There were no significant differences in character-
istics between patients in both ICUs, except that in the
adult ICU most of the patients had been referred from
another ward in the same hospital (Additional file 1:
Table S2). Therefore, we analyzed the data from the
ICUs both separately and pooled.
Overall, 158/412 (38.3%) patients had a positive cul-
ture with carbapenem-nonsusceptible A. baumannii-
calcoaceticus complex, the remaining 254 patients were
free from carbapenem-nonsusceptible A. baumannii-
calcoaceticus complex on admission and remained so
during their ICU stay. Sixty-nine patients (69/412;
16.7%) already carried carbapenem-nonsusceptible A.
baumannii-calcoaceticus complex as revealed by screen-
ing cultures taken on the day of ICU admission, 89/343
(25.9%) patients who were initially culture-negative
acquired carbapenem-nonsusceptible A. baumannii-
calcoaceticus complex during their ICU stay (Additional
file 2: Figure S1). Of the total of 158 patients with positive
cultures, the positive cultures were obtained from screen-
ing specimens only in 80 patients, from clinical specimens
only in 34 patients and from both screening and clinical
samples in 44 patients. Interestingly, of the patients that
were positive on ICU admission, 17 (24.6%) were admitted
directly from the emergency unit. Six patients had one or
more blood cultures with carbapenem-nonsusceptible A.
baumannii-calcoaceticus complex, and three of them died
on the ICU. The dynamics of acquisition of carbapenem-
nonsusceptible A. baumannii-calcoaceticus complex in
the ICU is shown in Fig. 1, 60% of patients that became
Fig. 1 Acquisition of carbapenem-nonsusceptible Acinetobacter baumannii-calcoaceticus complex in ICUs. Note: The solid line represents the cumulative
percentage of patients by first day of culture being positive for carbapenem-nonsusceptible A. baumannii-calcoaceticus complex during ICU stay. In total,
data from 89 patients are included in this figure. The median acquisition day (day 7, 60% of patients positive) is shown as well
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positive for carbapenem-nonsusceptible A. baumannii-
calcoaceticus complex during their ICU stay did so in
the first week of ICU stay. There were no differences in the
dynamics of carbapenem-nonsusceptible A. baumannii-
calcoaceticus complex acquisition between the two ICUs
(median acquisition day in adult ICU: 7, in ER-ICU:
6). The acquisition rate for carbapenem-nonsusceptible A.
baumanni-calcoaceticus complex was 43 per 1000
patient-days at risk overall, with an average of 43 per 1000
patient-days in the adult ICU and 43 per 1000 patient-
days in the ER-ICU.
Patient outcomes were clearly associated with
carbapenem-nonsusceptible A. baumanni-calcoaceticus
complex status of patients. Patients who acquired
carbapenem-nonsusceptible A. baumannii-calcoaceticus
complex during their ICU stay had a significantly lon-
ger length of stay (median [interquartile range (IQR)]:
11 [5–18], adjusted hazard ratio [aHR]: 2.56 [99%
confidence interval (CI): 1.76–3.70], p < 0.001, Add-
itional file 1: Table S4, particularly the group of pa-
tients that became positive before the day of their
discharge (median [IQR] 13 [8–23] days, p < 0.001,
Fig. 2) compared to the other groups of patients, of
which ≥80% were discharged from the ICU within ten
days. Interestingly, these latter groups not only in-
cluded the patients that were always free from
carbapenem-nonsusceptible A. baumannii-calcoaceticus
complex, but also included patients that already carried
carbapenem-nonsusceptible A. baumannii-calcoaceticus
complex at the time of admission to the ICU, and pa-
tients that remained free of carbapenem-nonsusceptible
A. baumannii-calcoaceticus complex until they were
found to be positive by screening on the day of their
discharge from the ICU (Fig. 2).
Acquisition of carbapenem-nonsusceptible A.
baumannii-calcoaceticus complex was not associated
with mortality, 23.2% of patients that remained free of
carbapenem-nonsusceptible A. baumannii-calcoaceticus
complex died versus 42.7% of patients that acquired
carbapenem-nonsusceptible A. baumannii-calcoaceticus
complex during their ICU stay (Fig. 3, p = 0.066; Add-
itional file 1: Table S3, multivariate analysis: adjusted
Fig. 2 Cumulative percentage of length of stay for patients according to their carbapenem-nonsusceptible Acinetobacter baumannii-calcoaceticus
complex status. Note: Lengths of stay (days) represent total days patients were hospitalized in the ICU. The red line represents patients that were
always carbapenem-nonsusceptible A. baumannii-calcoaceticus complex negative during their ICU stay. The blue line represents patients already
carbapenem-nonsusceptible A. baumannii-calcoaceticus complex positive on the day of admission. The green line represents patients that were
carbapenem-nonsusceptible A. baumannii-calcoaceticus complex positive only at the time of discharge and the black line represents patients that became
positive for carbapenem-nonsusceptible A. baumannii-calcoaceticus complex during their ICU stay before the day of discharge. P value:
comparison between patients that became positive with carbapenem-nonsusceptible A. baumannii-calcoaceticus complex before the day
of discharge and the other groups
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Odds Ratio (aOR):1.59 [99%CI: 0.74–3.40]). Importantly,
the admission SIRS and qSOFA scores of patients
with or without A. baumannii-calcoaceticus complex
acquisition did not differ (Table 1), indicating that the
difference in the risk of dying was not present at the time
of ICU admission but emerged later during their ICU stay
(SIRS: crude Odds Ratio (cOR):1.69 [99%CI:0.55–5.22],
p = 0.230; qSOFA:cOR: 1.45[99%CI:0.68–3.08], p = 0.211,
Additional file 1: Table S3).
Patients that were free of carbapenem-nonsusceptible
A. baumannii-calcoaceticus complex during their entire
ICU stay were less likely to have had prior exposure to
antibiotics, especially carbapenems (p < 0.01), they were
more likely to have had a surgical indication for their
admission to the ICU, and less likely to have had cere-
brovascular disease (Table 1). Patients that acquired
carbapenem-nonsusceptible A. baumannii-calcoaceticus
complex during ICU stay had undergone a procedure
(mechanical ventilation), had a medical device (central
venous catheter or urine catheter) or had received carba-
penem therapy more often than the other groups in the
univariate analysis (p < 0.01) (Table 1). In a multivariate
comparison of patients who acquired carbapenem-
nonsusceptible A. baumannii-calcoaceticus complex to
patients that were always negative, only carbapenem
therapy during ICU admission could be identified as a
risk factor (aOR: 3.37 [99%CI: 1.68–6.77], p < 0.01).
Carbapenem-nonsusceptible A. baumannii-calcoaceticus
complex and molecular characterization
In total, we collected 311 carbapenem-nonsusceptible iso-
lates from 158 patients, six carbapenem-nonsusceptible A.
baumannii-calcoaceticus complex isolates cultured from
the environment (table, bed rails, sinks, and tapwater),
and a single isolate from a healthcare worker (throat) that
was carbapenem-nonsusceptible as well (Additional file 1:
Table S5).
The blaOXA-23-like gene was demonstrated in 292/318
(91.8%) isolates including isolates from patients, the envir-
onment and from the healthcare worker. The blaOXA-24-like
gene was detected in a single isolate. Coexistence of OXA-
23 with other oxacillinases and carbapenemases was found:
OXA-23/OXA-58 (1 isolate), and OXA-23/NDM-1 (4 iso-
lates). The blaOXA-23-like gene was always demonstrated in
combination with the ISAba1 insertion element upstream
to the OXA-23 beta-lactamase. The intrinsic A.
baumannii-calcoaceticus complex gene blaOXA-51-like was
demonstrated in all isolates. In the subset of isolates
that were subjected to WGS (n = 14), the blaOXA-51-
Fig. 3 Survival analysis of ICU patients according to their carbapenem-nonsusceptible Acinetobacter baumannii-calcoaceticus complex status. Note:
Survival of patients with carbapenem-nonsusceptible A. baumannii-calcoaceticus complex acquired during their ICU stay (blue line) compared with the
survival of patients that remained negative for carbapenem-nonsusceptible A. baumannii-calcoaceticus complex in their screening and clinical cultures
(green line)
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Table 1 Patient characteristics and outcomes according to carbapenem-nonsusceptible A. baumannii-calcoaceticus complex status
Carbapenem-nonsusceptible
A. baumannii-calcoaceticus
complex positive on admission
Carbapenem-nonsusceptible
A. baumannii-calcoaceticus
complex acquired during ICU stay
Carbapenem-nonsusceptible
A. baumannii-calcoaceticus
complex negative
p value
n = 69 (n = 89) n = 254
Age (years), median (IQR) 47 (33–60) 48 (35.3–57) 46 (32–58) 0.700
Gender (%) 0.535
Male 35 (50.7) 42 (47.2) 137 (53.9)
Female 34 (49.3) 47 (52.8) 117 (46.1)
Underlying diseases (%)
Cardiovascular 0.024
Yes 9 (13.0) 3 (3.4) 13 (5.1)
No 60 (87.0) 86 (96.6) 241 (94.9)
Cerebrovascular 0.001
Yes 3 (4.3) 14 (15.7) 12 (4.7)
No 66 (95.7) 75 (84.3) 242 (95.3)
Chronic kidney disease 0.915
Yes 5 (7.2) 8 (9.0) 20 (7.9)
No 64 (92.8) 81 (91.0) 234 (92.1)
Diabetes mellitus 0.334
Yes 20 (29.0) 20 (22.5) 78 (30.7)
No 49 (71.0) 69 (77.5) 176 (69.3)
Malignancy 0.740
Yes 29 (42.0) 37 (41.6) 116 (45.7)
No 40 (58.0) 52 (58.4) 138 (54.3)
Indication for ICU admission (%) 0.002
Medical 32 (46.4) 38 (42.7) 70 (27.6)
Surgical 37 (53.6) 51 (57.3) 184 (72.4)
Referral from (%) 0.900
Other ward this hospital 38 (55.1) 48 (53.9) 136 (53.5)
Other hospital 14 (20.3) 14 (15.7) 49 (19.3)
Directly from Emergency Unit 17 (24.6) 27 (30.3) 69 (27.2)
Antibiotic exposure (pre-ICU admission)
Any antibiotic (%) 58 (84.1) 73 (82.0) 180 (70.9) 0.021
Carbapenem (%) 24 (34.8) 22 (24.7) 33 (13.0) <0.01
SIRS Score, (%) 0.916
Score≥ 2 64 (92.8) 81 (91.0) 232 (91.3)
Score < 2 5 (7.2) 8 (9.0) 22 (8.7)
qSOFA Score, (%) 0.089
Score≥ 2 51 (73.9) 78 (87.6) 205 (80.7)
Score < 2 18 (26.1) 11 (12.4) 49 (19.3)
Procedures (during ICU admission)
Mechanical ventilation (%) 63 (91.3) 88 (98.9) 220 (86.6) 0.004
Mechanical ventilation (days)
median(IQR)
5 (2–8) 8 (4–16) 3 (1–6)
≥ 5 days (%) 36 (52.2) 63 (70.8) 83 (2.7) <0.01
< 5 days (%) 33 (47.8) 26 (29.2) 171 (67.3)
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like gene involved was blaOXA-66 in 13 isolates and
blaOXA-68 in one isolate (Table 2).
Clonal relatedness
Raman spectroscopy analysis performed for all of the
isolates, revealed the presence of multiple types within
the collection of A. baumannii-calcoaceticus complex. In
total, 51 Raman types were identified. Interestingly, the
majority of strains belonged to one of five major clusters
(Additional file 3: Figure S2). The largest cluster (desig-
nated CIPTO-31) consisted of 111 isolates obtained
from 69 patients (screening and clinical specimens) and
four isolates from the environment. The sources of the
five major clusters are specified in Additional file 1:
Table 1 Patient characteristics and outcomes according to carbapenem-nonsusceptible A. baumannii-calcoaceticus complex status
(Continued)
Carbapenem-nonsusceptible
A. baumannii-calcoaceticus
complex positive on admission
Carbapenem-nonsusceptible
A. baumannii-calcoaceticus
complex acquired during ICU stay
Carbapenem-nonsusceptible
A. baumannii-calcoaceticus
complex negative
p value
n = 69 (n = 89) n = 254
Central venous catheter (%) 66 (95.7) 85 (95.5) 212 (83.5) <0.01
Central venous catheter (days)
median(IQR)
6 (3–9) 10 (5–17) 4 (2–7)
≥ 5 days (%) 41 (59.4) 71 (79.8) 111 (3.7) <0.01
< 5 days (%) 28 (40.6) 18 (20.2) 143 (56.3)
Urine catheter 69 (100) 89 (100) 254 (100) N/A
Urine catheter (days) median (IQR) 6 (3–10) 10 (6–18) 5 (3–7)
≥ 5 days (%) 26 (37.7) 13 (14.6) 122 (48.0) <0.01
< 5 days (%) 43 (62.3) 76 (85.4) 132 (52.0)
Antibiotic therapy (during ICU admission)
Any antibiotic (%) 68 (98.6) 89 (100) 249 (98.0) 0.411
Carbapenem (%) 42 (60.9) 62 (69.7) 95 (37.4) <0.01
Outcomes
Length of stay (days), median (IQR) 5 (3–9) 11 (5–18) 4 (3–7) <0.01
Death 22 (31.9) 38 (42.7) 59 (23.2) 0.002
Abbreviations: ICU, Intensive Care Unit; IQR, Interquartile range; qSOFA, quick Sepsis-related Organ Failure Assessment; SIRS, Systemic Inflammatory
Response Syndrome
Significance was calculated using Oneway ANOVA and Pearson Chi Square
A p-value less than 0.01 was considered statistically significant
Table 2 Results of MLST analyses of 14 carbapenem-nonsusceptible A. baumannii-calcoaceticus complex isolates
Sample number ST gltA gyrB gdhB recA cpn60 gpi rpoD OXA-51 group OXA-23 Raman cluster
171bl040813 new ST 1 15 3 2 2 164 3 OXA-66 + CIPTO-31
262bl211013 new ST 1 15 3 2 2 164 3 OXA-66 + CIPTO-31
275bl101013 new ST 1 15 3 2 2 61 3 OXA-66 + CIPTO-31
69E–bed-rails-4 new ST 1 15 3 2 2 164 3 OXA-66 + CIPTO-31
404re030714 195 1 3 3 2 2 96 3 OXA-66 + CIPTO-48
91EIGD1214 195 1 3 3 2 2 96 3 OXA-66 + CIPTO-48
156th250713 new allel/ST 1 3 3 2 2 new 3 OXA-66 + CIPTO-48
206bl020913 new allel/ST 1 3 3 2 2 new 3 OXA-66 + CIPTO-46
319bl020514 208 1 3 3 2 2 97 3 OXA-66 + CIPTO-46
207re300813 new ST 1 3 3 2 2 61 3 OXA-66 + CIPTO-45
422sp170714 new ST 1 3 3 2 2 61 3 OXA-66 + CIPTO-45
116sp080713 218 1 3 3 2 2 102 3 OXA-66 + CIPTO-30
176BA150813 218 1 3 3 2 2 102 3 OXA-66 + CIPTO-30
153bl290713 642 22 15 13 12 4 169 2 OXA-68 + CIPTO-39
Abbreviations: MLST, Multilocus Sequence Type; ST, Sequence Type
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Table S6. Strains belonging to the dominant cluster
CIPTO-31 were present in both ICUs throughout the
study period, whereas other clones seemed to wax and
wane over time (Fig. 4). Patients were colonized with
carbapenem-nonsusceptible A. baumannii-calcoaceticus
complex irrespective of the location of their bed in these
ICUs indicating that spreading of carbapenem-
nonsusceptible A. baumannii-calcoaceticus complex in
the ICUs was not restricted to only a part of the ICU
(Additional file 4: Figure S3).
MLST, performed for a subset of 14 isolates, revealed
the presence of multiple sequence types (STs), which cor-
responded closely to the Raman spectroscopy clustering
(Table 2). Four previously identified STs (ST195, ST208,
ST218, and ST642) as well as several new STs, and a new
allele for the gpi gene were found in this study (Table 2).
Discussion
This is the first report of a study on the clinical and
molecular epidemiology of carbapenem-nonsusceptible
A. baumannii-calcoaceticus complex in two ICUs in
a large academic hospital in Jakarta, Indonesia. These
two ICUs can be considered to have endemic
carbapenem-nonsusceptible strains belonging to A.
baumannii-calcoaceticus complex, i.e. entrenched by a
few carbapenem-nonsusceptible clones, whose acquisition
by patients may be associated with a prolonged ICU stay.
Carbapenem-nonsusceptible A. baumannii-calcoaceticus
complex has emerged globally as a hospital-acquired patho-
gen, causing many outbreaks, especially in ICUs [3]. In
Asia, carbapenem-resistant A. baumannii-calcoaceticus
complex were found to dominate in Vietnam [15], Thailand
[16], Malaysia [17], and also China [18]. Similar to these
studies, we found that 38.3% of the patients had
colonization or infection with carbapenem-nonsusceptible
A. baumannii-calcoaceticus complex. By screening on ICU
admission, 43.7% of the carbapenem-nonsusceptible A.
baumannii-calcoaceticus complex positive patients were
already colonized with this species prior to their admission.
This suggests that patients may become colonized with
Fig. 4 Persistence of Raman clones of carbapenem-nonsusceptible Acinetobacter baumannii-calcoaceticus complex in two ICUs of Dr. Cipto
Mangunkusomo General Hospital, Jakarta, Indonesia. Note: Endemic curves of the five biggest clusters of carbapenem-nonsusceptible A.
baumannii-calcoaceticus complex in each ICU, April–October 2013 and April–August 2014. The dark blue bars represent cluster CIPTO-30. The red
bars represent CIPTO-31. The green bars represent CIPTO-45. The yellow bars represent CIPTO-46 and the light blue bars represent CIPTO-48. The
x-axis indicates time of the study (by week). The y-axis indicates number of isolates
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such strains elsewhere in the same hospital or in another
hospital from which they are referred, or may come
with such strain directly from the community, pos-
sibly having acquired their strain during a previous
healthcare contact. Thus, the ICUs in this study experi-
ence a regular influx of patients carrying carbapenem-
nonsusceptible A. baumannii-calcoaceticus complex
strains into their setting. Our findings also raise questions
about carriage of A. baumannii-calcoaceticus complex in
the community, a finding that was also reported in a re-
cent study from Semarang, Central Java, Indonesia. From
the nasopharynx of 14 healthy people, A. baumannii-
calcoaceticus complex was isolated in that study [19]. This
requires further investigation.
Screening cultures can, therefore, be considered
very helpful for early detection, infection control, and
rational antibiotic use. A study in South Florida found
that patients with positive surveillance cultures had a
8.4-fold higher risk of developing a subsequent A.
baumannii-calcoaceticus complex infection compared
with patients who remained negative on surveillance
cultures [20].
Our data also show that many patients acquire
carbapenem-nonsusceptible A. baumannii-calcoaceticus
complex during their ICU stay and that these acquisi-
tions are associated with significantly longer ICU stay
but not with mortality (at the chosen level of signifi-
cance) compared to patients who did not acquire
carbapenem-nonsusceptible A. baumannii-calcoaceticus
while in the ICU. This is in agreement with a study from
the USA, which showed an independent association be-
tween multidrug-resistant A. baumannii-calcoaceticus
complex and increased hospital and ICU length of stay,
but not an increased mortality [21]. However, a recent sys-
tematic review and meta-analysis to examine the associ-
ation between carbapenem-resistant A. baumannii-
calcoaceticus complex (CRAB) and mortality found
that patients with CRAB had a significantly higher risk of
mortality than patients with carbapenem-susceptible A.
baumannii-calcoaceticus complex (crude OR = 2.22; 95%
CI = 1.66–2.98) [22].
The most prevalent mechanisms of carbapenem-
nonsusceptibility in A. baumannii-calcoaceticus com-
plex are acquired OXA-type carbapenem-hydrolyzing
beta-lactamases of the OXA-23, OXA-24 and OXA-58
subfamilies, and the New Delhi metallo-beta-
lactamases (NDM) [23–25]. Our study found that
91.8% of the isolates carried the blaOXA-23-like gene
in combination with the upstream presence of the
ISAba1 insertion element, enhancing carbapenem
resistance. blaOXA-24-like, blaOXA-58-like, and blaNDM-
like genes were rarely present. The dissemination of
OXA-23 producing carbapenem-nonsusceptible A.
baumannii-calcoaceticus complex isolates has
previously been reported in Asia and throughout the
world [26–28].
Carbapenem-nonsusceptible A. baumannii-calcoaceticus
complex colonizing/infecting ICU patients may originate
from the patient her/himself, but may also come from
contaminated hospital equipment and environment,
staff and other patients. Multiple reported outbreaks of
multidrug-resistant A. baumannii-calcoaceticus complex
infection were associated with environmental contamin-
ation [29–31]. There should be a focus on the prevention
of nosocomial transmission of these microorganisms from
these environmental sources to patients.
We performed Raman spectroscopy as a first bacterial
typing method [12]. This analysis revealed five clusters,
with the largest one (CIPTO-31), responsible for more
than one third of all isolates, persisting in both ICUs
throughout the study period. Geographical analysis of
cluster CIPTO-31 isolates showed spreading of this clone
throughout both ICUs. The isolates were found in and
around all the beds regularly occupied by patients. MLST
of four CIPTO-31 isolates revealed that these could be
assigned to two new STs. Another nine isolates from the
largest Raman clusters could be assigned to ST195,
ST208, or ST218, or a new ST based on a new allele for
the gpi gene (http://pubmlst.org/abaumannii/). A blood
culture isolate that was unique in the Raman spec-
troscopy typing belonged to ST642. ST195, ST208,
ST218, and ST642 have all previously been identified
in Asian countries [32], including China [33], Malaysia
[34], and Japan [35]. The epidemiology of carbapenem-
nonsusceptible A. baumannii-calcoaceticus complex in
this Indonesian hospital was a combination of several
known dominant Asian clones and new clones.
Our study has certain limitations. First, our study was
a single-center study during a situation of endemic
carbapenem-nonsusceptible A. baumannii-calcoaceticus
complex colonisation and infection. Therefore, our data
should not be considered to be representative for the
whole country. Second, we did not evaluate the effect of
other possible confounders, such as dialysis, need for
inotropes, surgery, and previous admission to a hospital.
Conclusions
In summary, this study is the largest to date that de-
scribes the characteristics and outcome of carbapenem-
nonsusceptible A. baumannii-calcoaceticus complex in
ICUs of a referral hospital in Indonesia. Colonization or
infection with carbapenem-nonsusceptible A. baumannii-
calcoaceticus complex during hospitalization was inde-
pendently associated with prolonged LOS in the ICU.
Prevention of A. baumannii-calcoaceticus complex
colonization and infection requires interventions di-
rected to source control and limiting the transmission
of such strains to and between patients.
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carbapenem-nonsusceptible Acinetobacter baumannii-calcoaceticus
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